



# Tagrisso in India

The CDSCO named-patient coordination pathway — indicative 2026

ONCOLOGY · EGFR-MUTANT NSCLC

## The clinical situation

Tagrisso (osimertinib) is a third-generation oral EGFR tyrosine kinase inhibitor that selectively targets sensitising EGFR mutations and the T790M resistance mutation while sparing wild-type EGFR. Manufactured by AstraZeneca. Eligibility requires molecular confirmation of an EGFR mutation from tumour tissue or liquid biopsy; dosing is typically 80 mg once daily continuously, with monitoring for diarrhoea, rash, QTc, and rare pneumonitis.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms EGFR status and documents a written clinical rationale and line history.
- 2 Administering facility confirmed.** An Indian tertiary oncology centre or licensed personal-use receiver is identified.
- 3 CDSCO named-patient application.** Clinical rationale, prescription, patient reference, product details, and chain-of-custody plan are filed.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Arrival & administration.** The pharmacy releases product against prescription; concierge coordinates monthly re-supply ahead of cycle end.

### Indicative economics

**Reference US cash-pay range:** USD 16,000–19,000 per 30-day supply. Logistics, customs handling, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-dose timing

**7–14 days** from a complete CDSCO application to first delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and CDSCO review. **Logistics.** Temperature- and chain-of-custody-compliant shipment. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Tagrisso × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/tagrisso-india.html](https://reservemed.com/access-guides/tagrisso-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team